Discover why LeMaitre's expansion in the peripheral vascular disease market and strong dividend growth make it an appealing ...

周五，Stifel对LeMaitre Vascular (NASDAQ:LMAT)股票进行了更新，将公司股票目标价从95美元上调至100美元，同时维持买入评级。这一调整是基于LeMaitre的第三季度表现，分析师将其描述为"令人鼓舞的超预期表现和上调指引"，强调公司的增长驱动因素正在达到或超过预期。

The company also reported progress in regulatory approvals, securing 14 out of 22 MDR CE Marks, and anticipates approval for Artegraft, its largest American product, in Europe by June 2025.

The company also exhibited significant progress in its regulatory approvals, receiving 14 out of 22 MDR CE Marks, and expects approval for Artegraft, its largest American product, in Europe by ...

The company also reported progress in regulatory approvals, securing 14 out of 22 MDR CE Marks, and anticipates approval for Artegraft, its largest American product, in Europe by June 2025. In terms ...

The company also exhibited significant progress in its regulatory approvals, receiving 14 out of 22 MDR CE Marks, and expects approval for Artegraft, its largest American product, in Europe by June ...

A: George LeMaitre, CEO, explained that the expansion is due to the territories being too large, especially after the Artegraft acquisition in 2020. The company is better equipped structurally now, ...